Empagliflozin or Semaglutide for Type 1 Diabetes
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Recruiting
Phase 2
Interventional Study
Diabetes
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 105 (estimated)
- Sponsor
- Mostafa Bahaa · Other
Who this trial is looking for
This trial is looking for overweight or obese adults with type 1 diabetes who have not been able to manage their blood sugar levels with insulin. Participants will be given either empagliflozin or semaglutide to see if it helps improve their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with type 1 diabetes for more than 1 year.
- I am between 18 and 65 years old.
- My BMI is 27 or higher.
- My HbA1c is between 7.5% and 10%.
- I have not controlled my diabetes well despite using multiple daily injections of insulin for at least 1 year.
You may not be able to join if
- I have a history of medullary thyroid cancer.
- I have ever used an insulin pump.
- I have used GLP-1 RAs or DPP-4 inhibitors.
- My kidney function is severely reduced (eGFR ≤ 30 mL/min/1.73 m2).
- I have liver disease with elevated liver enzymes.
- I have a history of pancreatitis.
- I am pregnant or breastfeeding.
- I have had a severe low blood sugar event requiring hospitalization in the last 3 months.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Type 1 Diabetes (T1DM) is a disease characterised by immune mediated destruction of the insulin-producing pancreatic beta cells. Overtime, obvious insulin deficiency develops which requires insulin therapy. T1DM accounts for about 5% to 10% of diabetes cases in Europe and United States. Currently, worldwide incidence is estimated to be around 15 per 100,000 people per year. Despite the advancement…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* patients diagnosed with type 1 diabetes for more than 1 year.
* Age 18-65 years.
* BMI ≥ 27 kg/m².
* HbA1c 7.5-10 % (58-86 mmol/mol)
* Inadequately controlled despite treatment with multiple daily injections of insulin for at least 1 year.
Exclusion Criteria:
History of medu…
Contacts
No contact information available.